Industry News
Stem cell review committee meets in Sydney
The independent committee appointed to review federal laws restricting stem cell research in Australia met for the first time yesterday, in Sydney. [ + ]
NeuroDiscovery to acquire UK firm, list on ASX
NeuroDiscovery, a Perth-based neurology-focused biotech company, has lodged an IPO prospectus with ASIC to raise funds and acquire 100 per cent of NeuroSolutions, a UK-based service provider and drug discovery company. [ + ]
Probiotec relocates to Victoria
Probiotec, which bought Agenix' Milton Pharmaceuticals division earlier this year, has relocated from Brisbane to Victoria. [ + ]
Fluorotechnics secures deal with Sigma Aldrich
Macquarie University spinoff Fluorotechnics is establishing a reputation for lucrative liaisons with giants, announcing a global marketing agreement with Sigma Aldrich for its new-tech FluoroProfile protein-quantification kits. [ + ]
Q3 dragged down local biotech in 04/05: Intersuisse
A lacklustre third quarter for Australian biotechnology stocks resulted in an overall fall of almost 20 per cent for the year ending June 2005, according to the Intersuisse Biotechnology Index. [ + ]
Mesoblast to establish ADR program
Adult stem cell company Mesoblast (ASX:MSV), which listed on the ASX six months ago, has appointed the Bank of New York to establish and maintain a Level 1 American Depositary Receipt (ADR) program. [ + ]
Safer HIV medicine
Patients suffering from chronic HIV infection are no longer under the risk of the deadly drug treatment reaction thanks to advances in genetic screening technology.
[ + ]Life Therapeutics sets out to acquire US firm Pyramid Biological
Sydney-based Life Therapeutics (ASX:LFE) has firmed up its stake in the global plasma supply industry, issuing a definitive letter of intent to acquire privately-held California-based Pyramid Biological for US$13 million, plus assumption of US$7 million debt. [ + ]
Bone Medical completes Phase I Perthoxal osteoporosis trial
Bone Medical (ASX:BNE) has completed a Phase I trial of its oral parathyroid hormone (PTH) product Perthoxal under development for the treatment of osteoporosis. [ + ]
Novogen bowel disease drug set to enter Phase I trial
Biopharmaceutical company Novogen's (ASX:NRT) anti-inflammatory compound NV-52 is set to enter Phase I trials at the Gold Coast Hospital. [ + ]
CogState sales topped $1m in 2004-05
Melbourne-based neurodiagnostic specialist CogState (ASX:CGS) says its sales exceeded AUD$1 million in sales for the 2004-05 fiscal year, up 420 per cent on the previous year, largely through sales to major pharmaceutical companies and research institutions. [ + ]
In brief: Rockeby, GTG, PharmAust, Mimotopes, Solbec
Rockeby Biomed (ASX:RBY) has lodged a prospectus to raise AUD$1.78 million through a non-renounceable one-for-one share rights issue. The issue price for each share is $0.01 and the company expects the capital to see it through to the end of financial year 2006. [ + ]
Marine research may benefit cancer patients
A team of international scientists – including Australians – has made a breakthrough in solving the problem that had put the development of marine-derived pharmaceuticals on hold for years.
[ + ]BioProspect cops Euro setback
Brisbane natural pesticide developer BioProspect (ASX:BPO) faced a setback this week, after its potential European licensee, Germany's W Neudorff, declined to pursue development of BioProspect's eucalyptus-derived biocide for carpet beetles and clothes moths. [ + ]
Apollo Life Sciences lists at premium
Sydney-based biopharmaceutical Apollo Life Sciences (ASX:AOP) has made a stellar debut on the ASX, at a 54 per cent premium to its offer price. [ + ]
